Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals
Clovis to acquire rights to discovery program for three additional targets for radionuclide therapy
▪ Clovis to pay approximately $12 million in upfront payments to 3B Pharmaceuticals
▪ Clovis currently planning to file an IND for…